A bioanalytical method for determination of eflornithine (DFMO) in 1000 microL human plasma has been developed and validated. DFMO and the internal standard (IS) were analysed by liquid chromatography with evaporative light-scattering detection (ELSD). Separation was performed on a Chirobiotic TAG (250 mm x 4.6 mm) column with ethanol (99.5%):0.01 mol/L acetic acid-triethylamine buffer at the rate of 25:75% (v/v) with flow rate of 1.0 mL/min. For d-DFMO in plasma the inter-assay precision was 6.5% at 75 micromol/L, 6.6% at 375 micromol/L and 5.8% at 750 micromol/L. For l-DFMO in plasma the inter-assay precision was 10.4% at 75 micromol/L, 6.5% at 375 micromol/L and 5.0% at 750 micromol/L. The lower limit of quantification (LLOQ) was determined to 25 micromol/L where the precision was 4.3% and 5.7%, respectively.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jchromb.2006.08.030 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating Difluoromethylornithine Safety and Efficacy for Non-Melanoma Skin Cancer Chemoprevention: A Systematic Review.
J Cutan Med Surg
November 2024
Cancer Research Program, McGill University Health Centre Research Institute, Montreal, QC, Canada.
Article Synopsis
- Recent FDA approval of difluoromethylornithine (DFMO) has sparked interest in its potential for preventing various cancers, including keratinocyte carcinomas (KCs), beyond its initial purpose for neuroblastoma in children.
- A systematic review of 12 studies involving 1,618 predominantly Caucasian patients revealed mixed results, with oral DFMO showing a significant reduction in KCs in only 24% of cases, while topical DFMO showed modest effectiveness in reducing actinic keratosis.
- Overall, the current evidence does not strongly support the use of oral DFMO, whereas topical DFMO may offer a better option for certain patients in preventing skin cancer.
The impact of thermophysical properties on eflornithine drug solute in acetone and ethyl acetate solvent interactions at varying concentrations and temperatures.
BMC Chem
August 2024
Department of Chemistry, College of Natural and Computational Science, Dambi Dollo University, P. O. Box. 260, Dambi Dollo, Oromia, Ethiopia.
The study was conducted on the impact of thermophysical properties on eflornithine drug solute-solvent interactions in aqueous ethyl acetate and acetone at different concentrations and temperatures. The aim of this study is to enhance the understanding of eflornithine's behavior in different solvents, which is crucial for its effective use in pharmaceutical applications. The density, molar volume, viscometric, and conductometric characteristics of the eflornithine drug solutions (0.
View Article and Find Full Text PDFUS Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy.
J Clin Oncol
September 2024
Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.
On December 13, 2023, the US Food and Drug Administration (FDA) approved eflornithine (IWILFIN, US WorldMeds) to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. The approval was based on an externally controlled trial (ECT) consisting of a single-arm trial, study 3(b), compared with an external control (EC) derived from a National Cancer Institute/Children's Oncology Group-sponsored clinical trial (Study ANBL0032) and supported by confirmatory evidence. In the protocol-specified primary analysis, the event-free survival hazard ratio (HR) was 0.
View Article and Find Full Text PDFDFMO inhibition of neuroblastoma tumorigenesis.
Cancer Med
May 2024
Department of Pediatrics, Penn State Health Children's Hospital, Hershey, Pennsylvania, USA.
Background: Most high-risk neuroblastoma patients who relapse succumb to disease despite the existing therapy. We recently reported increased event-free and overall survival in neuroblastoma patients receiving difluoromethylornithine (DFMO) during maintenance therapy. The effect of DFMO on cellular processes associated with neuroblastoma tumorigenesis needs further elucidation.
View Article and Find Full Text PDFImpact of Difluoromethylornithine and AMXT 1501 on Gene Expression and Capsule Regulation in .
Biomolecules
February 2024
Department of Comparative Biomedical Sciences, College of Veterinary Medicine, Mississippi State University, Mississippi State, MS 39762, USA.
(Spn), a Gram-positive bacterium, poses a significant threat to human health, causing mild respiratory infections to severe invasive conditions. Despite the availability of vaccines, challenges persist due to serotype replacement and antibiotic resistance, emphasizing the need for alternative therapeutic strategies. This study explores the intriguing role of polyamines, ubiquitous, small organic cations, in modulating virulence factors, especially the capsule, a crucial determinant of Spn's pathogenicity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!